Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Solid Biosciences Inc (SLDB)

Solid Biosciences Inc (SLDB)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Solid Biosciences Inc 500 RUTHERFORD AVENUE THIRD FLOOR CHARLESTOWN MA 02129 USA

www.solidbio.com Employees: 100 P: 617-337-4680

Sector:

Medical

Description:

Solid Biosciences LLC is a life science company. It focuses on developing therapies for Duchenne muscular dystrophy. The company is engaged in developing gene therapies, disease modifying therapies and assistive devices, all targeting the various facets of the DMD. Its product candidate includes SGT-001, a gene transfer candidate which is in Phase I/II clinical trial to restore functional dystrophin protein expression in patients' muscles. Solid Biosciences LLC is headquartered in Cambridge, Massachusetts.

Key Statistics

Overview:

Market Capitalization, $K 440,971
Enterprise Value, $K 360,731
Shares Outstanding, K 77,910
Float, K 76,430
% Float 98.10%
Short Interest, K 9,944
Short Float 12.76%
Days to Cover 10.86
Short Volume Ratio 0.58
% of Insider Shareholders 1.90%
% of Institutional Shareholders 81.46%

Financials:

Annual Sales, $ 0 K
Annual Net Income, $ -124,700 K
Last Quarter Sales, $ 0 K
Last Quarter Net Income, $ -45,780 K
EBIT, $ -169,700 K
EBITDA, $ -170,840 K

Growth:

1-Year Return 68.31%
3-Year Return -22.78%
5-Year Return -94.12%
5-Year Revenue Growth 0.00%
5-Year Earnings Growth 93.24%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -0.48 on 11/03/25
Next Earnings Date 03/05/26
Earnings Per Share ttm -2.38
EPS Growth vs. Prev Qtr -14.29%
EPS Growth vs. Prev Year 39.24%
Annual Dividend & Yield (Paid) 0.00 (0.00%)
Annual Dividend & Yield (Fwd) 0.00 (0.00%)
Dividend Payout Ratio 0.00%
Most Recent Split 1-15 on 10/28/22

SLDB Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -71.54%
Return-on-Assets % -58.27%
Profit Margin % 0.00%
Debt/Equity 0.00
Price/Sales N/A
Price/Cash Flow N/A
Price/Book 2.08
Book Value/Share 2.80
Interest Coverage -365.76
60-Month Beta 2.69
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar